Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175983 | 1.00 | GLO1 (0.37) | GLO1CYP2C9CYP2D6CYP2C19NPSR1 | |
| SCHEMBL10175985 | 0.87 | GLO1 (0.39) | GLO1CYP2C9CYP2D6CYP2C19NPSR1 | |
| SCHEMBL14210184 | 0.82 | CYP2D6 (0.34) | GLO1CYP2C9CYP2D6CYP2C19NPSR1 | |
| SCHEMBL58455 | 0.81 | GLO1 (0.35) | GLO1CYP2C9CYP2D6CYP2C19NPSR1 | |
| SCHEMBL22692406 | 0.80 | CYP2C9 (0.36) | GLO1CYP2C9CYP2D6CYP2C19NPSR1 | |
| SCHEMBL14210612 | 0.80 | GLO1 (0.34) | GLO1CYP2C9CYP2D6CYP2C19NPSR1 | |
| SCHEMBL12203122 | 0.78 | DPP4 (0.35) | GLO1CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL12203118 | 0.78 | DPP4 (0.35) | GLO1CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL14233246 | 0.78 | GLO1 (0.33) | GLO1CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL14211032 | 0.78 | GLO1 (0.33) | GLO1CYP2C9CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | GLO1 2768/4885CYP2C9 523/4885CYP2D6 279/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | GLO1 2564/4885CYP2C9 341/4885CYP2D6 242/4885 |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | GLO1 2768/4885CYP2C9 523/4885CYP2D6 279/4885 |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | DHCR7, CYP46A1, NR1H2 | GLO1 3786/4885CYP2C9 1900/4885CYP2D6 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.